Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia

Journal of Laboratory and Clinical Medicine

Volumn 143, Issue 5, 2004, Pages 269-283

  Feldman, Charles ^a,b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Division of Pulmonology   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPENICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTIBUTEN; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINCOSAMIDE DERIVATIVE; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN DERIVATIVE; STREPTOGRAMIN DERIVATIVE; SULFAMETHOXAZOLE; TELITHROMYCIN; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ALLERGY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG UTILIZATION; GENETIC ANALYSIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MEDICAL DOCUMENTATION; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PARAMETER; PREDICTION; PREVALENCE; REVIEW; STANDARD; STREPTOCOCCUS PNEUMONIAE; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT INDICATION;

EID: 2342489361     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lab.2004.02.002     Document Type: Review

References (93)

1. Moellering RC Jr. The continuing challenge of lower respiratory tract infections. Clin Infect Dis 2002;34(suppl 1):S1-3.
2. Pankey GA. Introduction. In: Ochsner clinic symposium on resistance and the use and misuse of antimicrobial therapy. Newton, Pa: Associates in Medical Marketing, 2000.
3. World Health Organization. WHO global strategy for containment of antimicrobial resistance. Available at: www.who.int/emc/amrpdfs/ WHO_Global_Strategy_English.pdf. Accessed April 4, 2004.
4. US Department of Health and Human Sciences. A USA public health action plan to combat antimicrobial resistance. Available at: www.cdc.gov/ drugresistance/actionplan/index/htm. Accessed April 4, 2004.
5. Centers for Disease Control and Prevention. CDC/National Center for Infectious Diseases website on antimicrobial resistance. Available at: www.cdc.gov/drugresistance. Accessed April 4, 2004.
6. Schrag SJ, Beall B, Dowell S. Resistant pneumococcal infections: the burden of disease and challenges in monitoring and controlling antimicrobial resistance. Available at: www.who.int/csr/drugresist/technicalguidance/ resistantinfection.pdf. Accessed April 4, 2004.
7. Felmingham D, Feldman C, Hryniewicz W, Klugman K, Kohno S, Low DE, et al. Surveillance of resistance in bacteria causing community-acquired respiratory tract infections. CMI 2002;8(suppl 2):12-42.
8. Garau J. Clinical failures: the tip of the iceberg? Respir Med 2001;95(suppl A):S5-11.
9. Cartwright K. Pneumococcal disease in western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002;161:188-95.
10. Bonomo RA. Resistant pathogens in respiratory tract infections in older people. J Am Geriatr Soc 2002;50:S236-41.
11. Finch R. Bacterial resistance: the clinical challenge. CMI 2002;8(suppl 3):21-32.
12. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard (ed 6). NCCLS document M7-A6. Wayne, Pa: National Committee for Clinical Laboratory Standards, 2003.
13. Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to β-lactam antibiotics. Arch Intern Med 2001;161:2538-44.
14. Austrian R, Gold J. Pneumococcal bacteremia, with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964;60:759-76.
15. Henry M, Leaf HL. Drug-resistant Streptococcus pneumoniae in community-acquired pneumonia. Curr Infect Dis Reports 2003;5:230-7.
16. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld L, et al. Prognosis and outcomes of patients with community-acquired-pneumonia. A meta-analysis. JAMA 1996;10:134-41.
17. Feikin DR, Schuchat A, Kolczak M, Banett NL, Harrison LH, Lefkowitz L, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000;90:223-9.
18. Pallares R, Linares J, Vadillo M, Cabellos C, Manresa F, Viladrich PF, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-80.
19. Metlay JP, Singer DE. Outcomes in lower respiratory tract infections and the impact of antimicrobial drug resistance. CMI 2002;8(suppl 2): 1-11.
20. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J 2002;20(suppl 36):3s-8s.
21. Hansman D, Bullen M. A resistant pneumococcus. Lancet 1967;2:264-5.
22. Klugman KP, Feldman C. Streptococcus pneumoniae respiratory tract infections. Curr Opin Infect Dis 2001;14:173-9.
23. Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J 1995;14:885-90.
24. Tan TQ, Mason EO Jr, Barson WJ, Wald ER, Schutze GE, Bradley JS, et al. Clinical characteristics and outcome of children with pneumonia attributable to penicillin-susceptible and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics 1998;102:1369-75.
25. Choi E-H, Lee H-J. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998;26:1346-54.
26. Watanabe H, Sato S, Kawakami K, Watanabe K, Oishi K, Rikitomi N, et al. A comparative clinical study of pneumonia by penicillin-resistant and -sensitive Streptococcus pneumoniae in a community hospital. Respirology 2000;5:59-64.
27. Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835-42.
28. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520-8.
29. Turett GS, Blum S, Fazal BA, Justman JE, Telzack EE. Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999;29:321-7.
30. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
31. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. CMI 2001;7:589-96.
32. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997;9(suppl 3):38-44.
33. Bryan CS, Talwani R, Stinson MS. Penicillin dosing for pneumococcal pneumonia. Chest 1997;112:1657-64.
34. Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001;33:797-805.
35. Kaplan SL, Mason EO Jr, Barson WJ, Tan TQ, Schutze GE, Bradley JS, et al. Outcome of invasive infections outside the central nervous system caused by Streptococcus pneumoniae isolates nonsusceptible to ceftriaxone in children treated with beta-lactam antibiotics. Pediatr Infect Dis J 2001;20:392-6.
36. Buckingham SC, Brown SP, San Joaquin VH. Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998;132:174-6.
37. Chesney PJ, Davis Y, English BK, Wang WC. Occurrence of Streptococcus penumoniae meningitis during vancomycin and cefotaxime therapy of septicemia in a patient with sick cell disease. Pediatr Infect Dis J 1995;14:1013-4.
38. Dowell SF, Smith T, Leversedge K, Snitzer J. Failure of treatment of pneumonia associated with highly resistant pneumococci in a child. Clin Infect Dis 1999;29:462-3.
39. Caballero-Granado FJ, Palomino-Nicas J, Pachon J, Garcia-Curiel A. Cefuroxime efficacy in treatment of bacteremic pneumonia due to penicillin-resistant and cefuroxime-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:1325-6.
40. Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-7.
41. Ailani RK, Alimchandani A, Hidalgo J, Ailani R, Buckley J, DiGiovine B. Cephalosporin-resistant pneumococcal pneumonia: does it affect outcome? Respir Med 2002;96:805-11.
42. Leclercq R, Courvalin P. Resistance to macrolides and related antibiotics in Streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:727-34.
43. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001;286:1857-62.
44. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithro mycin and clarithromycin. Clin Infect Dis 2000;31:1008-11.
45. Musher DM, Dowell ME, Shortridge VD, Flamm RK, Jorgensen JH, Le Magueres P, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002;346:630-1.
46. Kays MB, Wack MF, Smith DW, Denys GA. Azithromycin treatment failure in community-acquired pneumonia caused by Streptococcus pneumoniae resistant to macrolides by a 23S rRNA mutation. Diagn Microbiol Infect Dis 2002;43:163-5.
47. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen AO, Gareen IF, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-64.
48. van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams. J Antimicrob Chemother 2003;51:691-6.
49. Butler JC, Lennox JL, McDougal LK, Sutcliffe JA, Tait-Kamradt A, Tenover FC. Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis 2003;36:19-25.
50. Dixon JMS. Pneumococcus resistant to erythromycin and lincomycin. Lancet 1967;1:573.
51. Lynch JP III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002;34(suppl 1):S27-46.
52. Fogarty C, Goldschmidt R, Bush K. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000;31:613-5.
53. Amsden GW. Pneumococcal macrolide resistance - myth or reality? J Antimicrob Chemother 1999;44:1-6.
54. Bishai W. The in vivo-in vitro paradox in pneumococcal respiratory tract infections. J Antimicrob Chemother 2002;49:433-6.
55. Perez-Trallero EP. Pneumococcal macrolide resistance - not a myth. J Antimicrob Chemother 2000;45:401-2.
56. Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002;35:565-9.
57. Pihlajamaki M, Kotilainen P, Kaurila T, Klaukka T, Palva P, Houvinen P, et al. Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33:483-8.
58. Ho PL, Que TL, Tsang DNC, Ng TK, Chow KH, Seto WH. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong. Antimicrob Agents Chemother 1999;43:1310-3.
59. Brueggemann AB, Coffman SL, Rhomberg P, Huynh H, Almer L, Nilius A, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002;46:680-8.
60. Yokota S-I, Sato K, Kuwahara O, Habadera S, Tsukamoto N, Ohuchi H, et al. Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan. Antimicrob Agents Chemother 2002;46:3311-5.
61. Goldstein EJC, Garabedian-Ruffalo SM. Widespread use of fluoroquinolones versus emerging resistance in pneumococci. Clin Infect Dis 2002;35:1505-11.
62. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1-9.
63. Ambrose PG, Owens RC Jr. New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins. Semin Resp Crit Care Med 2000;21:19-32.
64. Balfour JAB, Lamb HM. Moxifloxacins, a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000;59:115-39.
65. Ho PL, Tse WS, Tsang KWT, Kwok TK, Ng TK, Cheng VCC, et al. Risk factors for acquisition of levofloxacin- resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-7.
66. Kays MB, Smith DW, Wack MF, Denys GA. Levofloxacin treatment failure in a patient with fluoroquinolone resistant Streptococcus pneumoniae pneumonia. Pharamacotherapy 2002;22:395-9.
67. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JCS, Kibsey P, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50.
68. Empey PE, Jennings HR, Thornton AC, Rapp RP, Evans ME. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001;35:687-90.
69. Kuehnert MJ, Nolte FS, Perlino CA. Fluoroquinolone resistance in Streptococcus pneumoniae. Ann Intern Med 1999;131:312-3.
70. Urban C, Rahman N, Zhao X, Mariano N, Segal-Maurer S, Drlica K, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-8.
71. Anderson KB, Tan JS, File TM Jr, DiPorsio JR, Willey BM, Low D. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003;37:376-81.
72. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-60.
73. Buckingham SC, Davis Y, English BK. Pneumococcal susceptibility to meropenem in a mid-South children's hospital. South Med J 2002;11:1293-6.
74. Perez-Trallero E, Marimon JM, Iglesias L, Larruskain J. Fluoroquinoione and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis 2003;9:1159-62.
75. Bauer T, Ewig S, Marcos MA, Schultze-Werninghaus G, Torres A. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med Clin North Am 2001;85:1367-79.
76. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999;107(suppl 1A):34S-43S.
77. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman K, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-408.
78. Metlay JP. Update on community-acquired pneumonia: impact of antibiotic resistance on clinical outcomes. Curr Opin Infect Dis 2002;15:163-7.
79. Azoulay-Dupius E, Rieux V, Muffat-Joly M, Bedos JP, Vallee E, Rivier C, et al. Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 2000;44:1575-7.
80. Rieux V, Carbon C, Azoulay-Dupius E. Complex relationship between acquisition of β-lactam resistance and loss of virulence in Streptococcus pneumoniae. J Infect Dis 2001;184:66-72.
81. Bedos JP, Rolin O, Bouanchaud DH, Pocidalo JJ. Relationship between virulence and resistance to antimicrobials in pneumococci: contribution of experimental data obtained in an animal model. Pathol Biol (Paris) 1991;39:984-90.
82. Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistance Streptococcus pneumoniae. Clin Microbiol Rev 1998:11:628-44.
83. File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;34(suppl 1):S17-26.
84. Finch RG, Low DE. A critical assessment of published guidelines and other decision-support systems for the antibiotic treatment of community-acquired respiratory tract infections. CMI 2002;8(suppl 2):69-91.
85. Craig WA. Re-evaluating current antibiotic therapy. Respir Med 2001;95(suppl A):S12-9.
86. Martinez JA, Horcajada JP, Almela M, Marco F, Soriano A, Garcia E, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003;36:389-95.
87. Waterer G, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
88. Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003;47:1151-3.
89. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt-Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. J Antimicrob Chemother 2000;46:973-80.
90. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730-54.
91. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
92. Mandell LA, Peterson LR, Wise R, Hooper D, Low DE, Schaad UB, et al. The battle against emerging antibiotic resistance: should fluoroquinolones be used to treat children? Clin Infect Dis 2002;35:721-7.
93. Hoshino K, Watanabe HK, Sugita R, Asoh N, Ntabaguzi SA, Watanabe K, et al. High rate of transmission of penicillin-resistant Streptococcus pneumonias between parents and children. J Clin Microbiol 2002;40:4357-9.